Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5486MR)

This product GTTS-WQ5486MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5486MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1914MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ2120MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ10554MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ8945MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ3956MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ66MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ1210MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ15893MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW